
|Videos|November 10, 2016
Evolving NCCN Guidelines for MPNs
Author(s)Ruben A. Mesa, MD
Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN Clinical Practice Guidelines for myeloproliferative neoplasms (MPNs) and who the recommendations will transition over the next year. Mesa spoke on the topic during an interview at the 34th Annual Chemotherapy Foundation Symposium™, held November 9-11, 2016 in New York City.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews
3
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
4
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
5






































